Instructions for authors

  • HOME
  • Instructions for authors

General information

Journal of Medicine and Life Science (JMLS), abbreviated 쏪 Med Life Sci, is the official publication of the Institute for Medical Science at Jeju National University. It is a peer-reviewed, open-access journal focused on delivering high-quality scientific research on general medicine. It is published mainly in Korean but also publishes English articles.

The journal was launched in December 2003 andoperated under the name 쏷he Cheju Journal ofMedicine (pISSN 1738-1010) until May 2009. Thejournal셲 name was changed to 쏷he Journal of Medicineand Life Science in May 2009. The journal has beenpublished exclusively online since March 2019 (eISSN2671-4922), and the journal셲 name was changed to 쏪ournal of Medicine and Life Science in April 2021.

The journal was published twice a year: on June 30th and December 31st until 2018, and three times a year: on April 30th, August 31st, and December 31st from 2019. It has been published four times a year: on March 31st, June 30th, September 30th, and December 31st since 2023, and has been rescheduled to three times a year: on January 31st, May 31st, and September 30th from January 2024. Special issues may be published when necessary. Anyone who would like to submit a manuscript to the JMLS is advised to read this journal셲 aims and scope section carefully. Manuscripts for submission to the JMLS should be prepared according to the instructions that follow. For issues not addressed in the journal셲 instructions, the author is referred to the International Committee of Medical Journal Editors (ICMJE) 쏳ecommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (

Table of Contents

Aims and scope

JMLS aims to publish scientific research articles from various medical science disciplines, with a specific interest in the d isea ses, medical conditions, and healthcare system of Jeju Island. Readers can access published articles at, and authors can submit their articles at The JMLS셲 articles are open-access articles distributed under the terms of the Creative Commons Attribution Non-Commercial License (, which permits unrestricted use, distribution, and reproduction in any medium when the original work is properly cited.

Research and publication ethics

The jou rna l ad heres to the g uidelines a nd best practices published by professional organizations, including Recommendations from the ICMJE and Principles of Transparency and Best Practice in Scholarly Publishing (joint statement by COPE, DOAJ, WAME, and OASPA; Manuscripts submitted to this journal must comply with the following research and publication ethics:

1. Authorship and Author셲 Responsibility
Authorship criteria are 1) substantial contributions to the study셲 conception and design, data acquisition, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content. All authors must grant final approval for the manuscript version to be published. They must also agree to be accountable for all aspects of the work and ensure that any questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Authors should meet either 1 or 2 to be considered authors and agree to the responsibilities listed above.
A ny requests for changes in authorship (adding author(s), deleting author(s), or re-arranging the order of authors) after initial manuscript submission and before publication should be explained in writing to the editor in a letter or e-mail signed by all authors of the paper. A copyright assignment must be completed by every author.
There is no limitation on the number of authors. Persons who do not meet the authorship criteria may be indicated as contributors in the Acknowledgments section. Descriptions of co-first authors or cocorrespond ing authors are also accepte dif the corresponding author believes that contributions to the manuscript warrant such roles.
The corresponding author should be available throughout the submission and peer review processes to respond to editorial queries and critiques of the work in a timely manner. The corresponding author should cooperate with any requests from the journal for data, additional information, or questions about the paper even after the paper is published.
2. Originality, Plagiarism, and Duplicate Publication
All manuscripts submitted to the JMLS should be original work that should not be published or be under consideration for publication by any other scientific journal. In whole or in part, accepted manuscripts should not be duplicated in any other scientific journal without the permission of the JMLS Editorial Board. Figures and tables can be used freely if the original source is verified according to the Creative Commons license.
It is mandatory for all authors to resolve any copyright issues when citing a figure or table from a journal that is not open-access. Submitted manuscripts are screened for possible plagiarism or duplicate publication using Crossref Similarity Check ( upon their submission.
If plagiarism or duplicate publication are detected in manuscripts submitted to this journal, the manuscripts may be rejected, the authors details published in the journal, and their institutions will be informed. There will also be penalties for the authors violating this regulation. Anyone who violates this regulation and/or general ethical principles of research will be banned from submitting papers to this journal for two years.
3. Secondary Publication
It is possible to republish manu scripts if they satisfy the condition of secondary publication as per Recommendations from ICMJE. These are:
  • The authors have received approva l from the editors of both journals (the editor concerned with the secondary publication must have access to the primary version).
  • The priority of the primary publication is respected by a publication interval negotiated by the editors of both journals and the authors.
  • The paper for secondary publication is intended for a different group of readers; an abbreviated version could be sufficient.
  • The secondary version faithfully reflects the data and interpretations of the primary version.
  • The secondary version informs readers, peers, and documenting agencies that the paper has been published in whole or in part elsewhere봣or example, with a note that might read, 쏷his article is based on a study first reported in the [journal title, with full reference]앪봞nd the secondary version cites the primary reference.
  • The title of the secondar y publication shou ld indicate that it is a secondary publication (complete or abridged republication or translation) of a primary publication. Of note, the United States Nationa l Libra r y of Med icine (NLM) does not consider translations to be 쐒epublications and does not cite or index them when the original article was published in a journal that is indexed in MEDLINE.
4. Conflict-of-interest Statement
The corresponding author must inform the editor of any potential conflicts of interest that could influence the authors interpretation of their study셲 data. A conflict of interest exists when an author or the author셲 institution, reviewer, or editor, has financial or personal relationships that could inappropriately influence or bias their actions. Such relationships are also known as dual commitments, competing interests, or competing loyalties. These relationships vary from being negligible to having great potential for influencing judgment. Not all relationships represent a true conflict of interest.
On the other hand, the potential for a conflict of interest can exist regardless of whether an individual believes that the relationship affects their scientific judgment. Financial relationships such as employment, consultancies, stock ownership, honoraria, and paid expert testimony are the most easily identifiable conflicts of interest and are most likely to undermine the credibility of the journal, the authors, or the work itself.
Conf licts of interest can occur for other reasons as well, such as persona l relationships, academic competition, and intellectual passion ( If there are any conflicts of interest, the authors should disclose them in the manuscript. Conflicts of interest may manifest during the research process itself; even for these, it is important to provide disclosure. The disclosure helps editors, reviewers, and readers approach the manuscript with an understanding of the situation and background of the completed research.
5. Statement of Human and Animal Rights
Clinical research should be conducted in accordance with the requirement of an institutional or regional 쏞linical Trial Ethics Committee that reviews the ethics of clinical research. Clinical research must also be conducted in accordance with the WMA Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects ( Clinical studies that do not meet the Helsinki Declaration will not be considered for publication.
For publication, human participants identifiable information, such as patients names, initials, hospital numbers, dates of birth, or other protected healthcare information, should not be disclosed. If you want to publish a facial photo of a subject, cover their eyes and delete information about the subject from radiographs. If it is not possible to cover the patient셲 eyes, it can be published with the consent of the patient.
For animal participants, research should be performed based on the National or Institutional Guide for the Care and Use of Laboratory Animals, and the ethical treatment of all experimental animals should be maintained. In principle, it should be stated in the manuscript that the experimental process does not conflict with the ethics committee regulations of the research institute or the Animal Protection Act.
6. Statement of Informed Consent and Institutional Review Board Approval
Copies of written informed consent should be kept for studies involving human participants. For clinical studies with human participants, there should be a certificate, an agreement, or approval by the Institutional Review Board (IRB) of the institution with which the author is affiliated. If necessary, the editor or reviewers may request copies of these documents to resolve questions about IRB approval and study conduct. In addition, for studies conducted with human participants, the method by which informed consent was obtained from the participants should be stated in the Methods section.
7. Registration of Clinical Trial Research
It is recommended that any research that deals with a clinical trial be registered with a primary national clinical trial registration site, such as, or other sites accredited by the World Health Organization as listed at or (, a service of the US National Institutes of Health.
8. Process for the Management of the Research and Publication Misconduct
When the journal faces suspected cases of research and publication misconduct, such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, an ethical issue with the submitted manuscript, a reviewer who has appropriated an author셲 idea or data, complaints against editors, and other issues, the resolving process will follow the flowchart provided by the Committee on Publication Ethics ( The discussions and decisions concerning the suspected cases will be carried out by the Editorial Board. For other related matters, the regulations of the Jeju National University Research Ethics Committee apply.
9. Editorial Responsibilities
The Editorial Board will cont i nuou sly work to monitor and safeguard the following publication ethics: guidelines for retracting articles; maintaining the integrity of academic records; precluding business needs from compromising intellectual and ethical standards; publishing corrections, clarifications, retractions, and apologies when needed; and excluding plagiarism and fraudulent data.
The editors maintain the following responsibilities: to reject and accept articles; to avoid any conflict of interest with respect to articles they reject or accept; to promote the publication of corrections or retractions when errors are found; and to preserve the anonymity of reviewers.
10. Data Sharing Statement
We adopt the ICMJE Recommendations for data sharing statement policy ( Authors may refer to the editorial, 쏡ata Sharing statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors, in JKMS vol. 32, no. 7:1051-1053 (

Copyrights/Open access/Deposit/Archiving policy

1. Copyright
Copyright to all published material belongs to the Institute for Medical Science at Jeju National University. The authors are required to agree to copyright transfer after their manuscript passes review. When the copyright transfer agreement is submitted to the journal, it is recognized that the author has approved the publication of the manuscript.
2. Open-access Policy
JMLS is an open-access journal, and full-text PDF files are available on the official website ( Articles are distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted, non-commercial use, distribution, and reproduction in any medium, provided that the original work is properly cited. To use any tables or figures published in JMLS in other periodicals, books, or media for scholarly and educational purposes, permission from the publisher of the JMLS is not necessary.
3. Deposit Policy
According to the deposit policy (self-archiving policy) of Sherpa/Romeo (, authors cannot archive pre-print (i.e., pre-refereeing) but may archive post-prints (i.e., final draft post-refereeing) and publisher셲 version/PDF.
4. Archiving Policy
JMLS provides the electronic backup and preservation of access to the journal셲 content by archiving in the National Library of Korea for the event that the journal is no longer published.

Manuscript Submission

Authors should submit manuscripts via the JMLS electronic manuscript management system ( Please log in first as a member of the system and follow the presented directions. Manuscripts should be submitted by the corresponding author, who should indicate the address, phone number, and e-mail address for correspondence on the title page of the manuscript. The revised manuscript should be submitted through the same web system using the same identification numbers.

Online submission process:
1) Go to
2) Log in (or click the 쁱egistration option, if you are a first-time user of
3) Click on 쁭ew submissions.
4) Check and confirm the 쏿uthor셲 manu script checklist.
5) Proceed with the following 8-step process.
  • Step 1. Fill in the manuscript type, title, running title, abstract, keywords, and corresponding author.
  • Step 2. Fill in the author(s) names and affiliation(s).
  • Step 3. Upload manuscript file.
  • Step 4. When the conversion is completed, please click the 쏮ake PDF button.
  • Step 5. Write the additional notes to the Editorin-Chief in the cover letter field and respond to the additional information below.
  • Step 6. Suggest reviewers.
  • Step 7. Confirm preview contents. If you agree to submit the manuscript, please click the 쐓ubmit button.
  • Step 8. Your submission is complete. You will receive your registration number or return notice via e-mail.
If you have any questions about the online submission process, contact the Editorial Office by e-mail at jmls. or by telephone at +82-64-754-8023.

Editorial and Peer Review Process

All manuscripts are initially reviewed by the JMLS editor. Submissions that are clearly outside the scope of the JMLS will be declined without further review. Manuscripts that are so poorly written or incomplete that it hampers the review process will also be declined but with the option of resubmission if the relevant concerns have been addressed. The Editorial Board may request the corresponding author to enhance the quality of the manuscript. All submitted manuscripts are analyzed with plagiarism detection software prior to undergoing editorial review.
Manu scripts are sent to the two most relevant reviewers available to review the contents. The editor selects peer referees by recommendation of the JMLS셲 Editorial Board members or from the Board`s specialist database. If the results of the first two reviewers differ, an additional review may be requested. The journal adopts double-blind peer-reviews, in which reviewers do not have access to the identities of the authors and vice versa. All manuscripts from editors, employees, or members of the editorial board are processed in the same way as other unsolicited manuscripts. During the review process, they will not engage in the selection of reviewers and decision process. These manuscripts are reviewed by other institutions that are not related to the manuscript's authors. Editors will not handle their own manuscripts, even if they are commissioned ones.
All manuscripts from editors, employees, or members of the editorial board are processed in the same way as other unsolicited manuscripts. During the review process, they will not engage in the selection of reviewers and decision process. These manuscripts are reviewed by other institutions that are not related to the manuscript셲 authors. Editors will not handle their own manuscripts, even if they are commissioned ones.
The existence of a manuscript under review is not revealed to anyone other than the peer reviewers and editorial staff. Peer reviewers are required to maintain confidentiality regarding the manuscripts they review and must not divulge any information about a specific manuscript or its content to any third party without prior permission from the journal셲 editors.
Information from submitted manuscripts may be systematically collected and analyzed as part of research to improve the quality of the editorial or peer review process. Identifying information remains confidential. Final decisions regarding manuscript publication are made by an editor who does not have any relevant conflicts of interest. All correspondence, including the editor셲 decision and requests for revisions, will be conducted via e-mail. The final decision regarding the publication of the manuscript is made by the Editorial Board, and the decision is either 쏿ccept, 쓒inor revision, 쓒ajor revision, or 쓗ejection.
Minor or major revisions of the manuscript may be recommended to the author based on the outcome of the review. If the author accepts the Editorial Board셲 recommendation, the revised manuscript should be accompanied by a Response to Reviewers Comments Letter that includes responses to the reviewer셲 comments and explanations regarding how the manuscript has been revised.
Upon resubmission, the Editoria l Board decides whether or not to publish the manuscript after a second deliberation. If the decision to request reexamination is repeated twice as a result of deliberation, this will be considered as the manuscript being rejected.
The duration of time for a first decision without review will normally be made within five days (median). Within 14 days of the reviewers agreement to review the submission, the reviewers comments will be sent to the corresponding author. Revised manuscripts must be submitted online by the corresponding author. Failure to resubmit the revised manuscript within 90 days of the editorial decision is regarded as a withdrawal. The Editorial Office should be notified if additional time is needed or if an author chooses not to submit a revision.
All authors are required to confirm the following publication conditions prior to their manuscript being considered:
  • a. If the manuscript does not introduce a new result or conclusion, then it should not have the same title as a previously published review article.
  • b. Once a case has been published in an original paper, it may not be reproduced as a case report. However, only in circumstances in which a novel diagnostic method, a novel therapeutic trial, or a previously unknown accompanying condition is found will the Editorial Board determine the possibility of acceptance.
  • c. Clinical trials on drugs with commercial implications will be reviewed by the proper subcommittee or subspecialty before being reviewed for publication.
  • d. Clinical letters of previously published cases will not be accepted. The Editorial Board will make an exception only if the case is very rare. The JMLS index should be reviewed before the submission of clinical letters.
  • e. Rejected manuscripts may not be resubmitted.
  • f. The manuscript will be rejected if the author does not address the comments made by the reviewer(s) or the manuscript does not follow the required guidelines.
1. General Principles
  • 1) JMLS publishes original articles, reviews, case reports, and letters.
  • 2) Manuscripts for publication in the JMLS should not have been previously published and should not have been submitted for publication elsewhere. Any conflicts of interest of all listed authors should be stated.
  • 3) The manuscript should be written according to the prescribed format. If not, the Editorial Board may return it before reviewing it. The Editorial Board decides on publication and may modify a portion of the text with little effect on the original.
  • 4) The manuscript셲 text, including tables and their footnotes and figure legends, must be doublespaced and in a standard 12-point font on A4 paper size.
  • 5) Tables and figures should be inserted on individual separate pages per table and figure.
  • 6) All pages should be numbered consecutively in the middle of the bottom margin, starting with the title page.
  • 7) In principle, manuscripts should be written in either Korean or English.
  • 8) Korean manuscripts are written according to Korean spelling, and academic terms are used as they are. If it is difficult to convey meaning with a translated term, when the problematic term is first used, it may be written in Chinese characters or the term셲 original language in parentheses next to the translated term. The translated term can then be used.
  • 9) When using a foreign language, ensure that terms are case-sensitive. If a word is difficult to translate because it is a proper noun, such as the name of a person or place, the original language should be used.
  • 10) Except f or u nits o f m easurement, a bbreviations are strongly discouraged. Do not use abbreviations in the title or abstract; limit their use in the text. Expand all abbreviations at first mention in the text.
  • 11) Measurements of length, height, weight, and volume should be reported in metric units (meter, kilogram, or liter), and laboratory values should be displayed in the International System of Units (SI) format.
2. Cover Letter
The cover letter accompanying the manuscript must specify the manuscript type and include statements on ethical issues and conflicts of interest and complete contact information for the corresponding author. The cover letter should include the following statement: 쏛ll authors have read and approved the submitted manuscript. The manuscript has not been submitted or published elsewhere in whole or in part, except as an abstract (if relevant).
The cover letter may include the names of up to three potential reviewers whom the authors would like to suggest, especially members of the Editorial Board. The authors may also include the names of up to three reviewers whom they would like not to evaluate their submission. The journal editor ultimately decides who will review the manuscript.
3. Article Type
Original Article
Original articles are papers reporting the results of basic or clinical investigations, which are sufficiently well documented to such an extent that they would be acceptable to critical readers. The manuscript should be prepared according to the Recommendations of the ICMJE. The manuscript should be in the following sequence: Title page, Abstract, and Key words, Introduction, Materials and Methods, Results, Discussion, Ack nowledgment, References, Tables, and Figure Legends.
Review Articles
Reviews may be written by the Editorial Board 셲 invitation a nd shou ld provide concise reviews of important subjects related to medical research. Reviews are organized as follows: Title page, Abstract, Keywords, Introduction, Main text, Conclusion, Acknowledgments, References, Tables, and Figure legends.
Case Report
Case reports are organized as follows: Title page, Abstract, and Keywords, Introduction, Case Report, Discussion, Acknowledgment, References, Tables, and Figure legends.
A letter is a type of brief communication on any topic that attracts the attention of the journal셲 readers. It should be brief, clear, and conclusive. No abstraction is required, and the body of the letter need not take any particular structure.
Requirements for article type
Article Type Length (Korean / English) Abstract (Only English) Keywords Reference Figures and Tables
Original Article 돞4,000 words 돞250 words 돞5 돞40 돞7
Review article 돞4,000 words 돞250 words 돞5 돞60 돞7
Case report 돞1,500 words 돞200 words 돞5 돞10 돞5
Letter 돞750 words - - 돞5 돞2
4. Title Page
The title page should contain the following information:
  • title (less than 50 Korean characters or 150 English letters): The title should be concise and representative of the manuscript셲 content. Avoid using abbreviations in the title.
  • author list (full names, position, academic degree of all authors): If there are two or more authors, list them according to their contribution to the research and manuscript writing. Separate the authors names with commas. When authors have different affiliations, each affiliation must be indicated in the order of the authors. Affiliations are classified using superscripts. The Editorial Board should be able to confirm the author셲 position. If you belong to a university, you must indicate your position as 쏱rofessor, Lecturer, Student, and if you belong to an elementary or secondary school, you must indicate that you are a 쏷eacher, Student (grade). If an author has no affiliation or position, only the author셲 name is indicated. Note that authors positions are not specified in the final publication.
  • Affiliation of authors: The author셲 affiliation should be written in the format 쐕niversity, department, and research institute. If authors with different affiliations are included, the main institution where the research was conducted should be recorded first. For other institutions, the front superscript is given in the order of the author셲 superscript, and the affiliation is indicated. The manuscript셲 title, author, and affiliation should be centered.
  • acknowledgment of research support
  • name, address, telephone, fax number, and e-mail address of the corresponding author
  • a running title should be written with a maximum of either 20 Korean characters or 10 English words.
5. Abstract and Keywords
The abstract should concisely describe the purpose, methods, results, and conclusion of the study in a non-structured format. Abbreviations, if needed, should be kept to an absolute minimum, and their first use should be preceded by the full term in words. The abstract should not include footnotes, references, or tables. The abstract can be modified by an English language reviewer appointed by the Editorial Board. For the selection of keywords, refer to Medical Subject Headings (MeSH;
6. Introduction
The introduction should provide the background of the study and state the specific purpose of the research and the hypothesis tested by the study. It may mention previous publications that are closely related to the article.
7. Materials and Methods
The materials and study design should be presented in detail. In experimental research, methods should be described in such a manner that the experiments can be reproduced by other researchers in the same field. The sources of special chemicals or preparations should be given (name of company, city, state, and country).
Clinical studies or experiments using laboratory animals or pathogens should have approval from the relevant committees. A statement concerning IRB approval and consent procedures must be presented in this section.
Authors must clearly describe the selection of observational or experimental participants (healthy individuals or patients, including controls), including eligibility and exclusion criteria and a description of the source population. Because the relevance of such variables as age, sex, or ethnicity is not always known at the time of study design, researchers should aim for the inclusion of representative populations in all study types and should, at a minimum, provide descriptive data for these and other relevant demographic variables.
Ensure the correct usage of the term sex (when reporting biological factors) and gender (identity, psychosocial or cultural factors), and, unless inappropriate, report the sex and/or gender of study participants, the sex of animals or cells, and describe the methods used to determine sex and/or gender. If the study was done with an exclusive population, for example, a study with only one sex, the authors should justify why this is the case, except in obvious cases (e.g., prostate cancer). Authors should define how they determined race or ethnicity and justify their relevance.
8. Results
This section should include a concise textual description of the data presented in the tables and figures. Excessive repetition of table or figure content should be avoided.
9. Discussion
Observations pertaining to the results of research and other related materials should be interpreted for your readers. Emphasize new and important observations; do not merely repeat the contents of the results. Explain the meaning of the observed results along with their limits, and within the limits of the research results, connect the conclusion to the purpose of the research. In a concluding paragraph, summarize the result and its meaning.
10. Acknowledgment
The Acknowledgments section should contain brief statements of assistance and financial support. Any other matters associated with research funds, facilities, and drugs that were used in the study should also be mentioned in this section.
Authors are recommended to have Open researcher and contributor IDs (ORCID). To receive an ORCID, authors should register on the ORCID website
12. References
References are cited on ly as necessar y, and the recorded references must be cited in the text. References are written in English regardless of the language used in the manuscript. References should be listed in the order they are cited in the text, with the corresponding number (Va ncouver or N Engl J Med style). If the reference is not in English, indicate the language used at the end of the document. When citing the author셲 name in the text, write the last name in English. It is used as the superscript 1 when indicating references in the manuscript. If there are two references, insert a comma between the numbers, and if there are three or more, add a hyphen to indicate that they are consecutive numbers.
The reference style for journal articles is as follows:
names of authors, the full title of the article, journal name abbreviated in accordance with MEDLINE, year, volume, and page numbers. List all authors when there are six or less authors; when there are seven or more authors, list the first six and add 쐃t al. All authors must be listed by their last name and the initials of their first and middle names. In the title of the reference, only the first letter is capitalized, and except for the scientific name, italics are not used. In the case of journals listed in Index Medicus, the abbreviation is used for the name of the journal, and for non-registered journals, the unique abbreviation determined by the journal is used. Papers in press may be listed with the journal name and tentative year of publication.
The reference style for a chapter of a book is as follows:
author and title of the chapter, editor of the book, the title of the book, edition, volume, place, publisher, year, and page numbers. Only cite unpublished data or personal communications in the text and not include these in the reference list. Internet URLs should be as follows; authors names, website title, URL, and the date of the latest update. All other references should be listed as shown in the Recommendations from the ICMJE. Authors are responsible for the accuracy and completeness of their references.
Examples of reference styles
  • Journal article
  • 1. Yang SW, Han S, Kim YR, Kim SH. The analysis of myeloid-derived suppressor cel ls in cancer patients with neutropenia to evaluate the effect of granulocytes colony stimulation factor. J Med Life Sci 2017;14:45-7.
  • 2. Zykova TA, Zhu F, Wang L, Li H, Lim DY, Yao K, et al. Targeting PRPK function blocks colon cancer metastasis. Mol Cancer Ther 2018. (Epub ahead of print)
  • 3. Jeong WS, Yoo JR, Heo ST. Infective endocarditis presented with septic sacroiliitis. J Med Life Sci 2017;14:70-3. (Korean)
  • Book
  • 4. Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGraw-Hill; 2002. p.93-113.
  • Website
  • 5. National Cancer Institute. Cancer genome anatomy project [Internet]. Bethesda, MD: National Cancer Institute; c2011[cited 2011 Mar 20]. Available from:
13. Tables
  • 1) Each table should be inserted on a separate page, with the table number, title and legend.
  • 2) Tables numbers should be in Arabic numerals in their order of mention.
  • 3) Tables titles should be concise. The first character should be capitalized.
  • 4) Tables should be concise and should not duplicate information found in figures.
  • 5) The significance of the results should be indicated by appropriate statistical analysis.
  • 6) Unnecessary longitudinal lines should not be avoided. Horizontal lines should be used as sparingly as possible.
  • 7) All symbols and abbreviations should be described below the table. The symbol style is as follows: *, , , 짠, , **
  • 8) Use superscript letters (a, b, c) to mark each footnote and ensure that each footnote in the table has a corresponding note. List abbreviations in the footnote section and explain any empty cells.
  • 9) When citing tables in the text, follow the 쒿able 1 format.
14. Figures and Figure Legends
  • 1) Figures should be submitted separately from the text of the manuscript. All pictures and photographs should be of excellent quality and supplied as JPEG, TIFF, or PowerPoint files with a resolution of more than 300 dpi. The preferred figure size is 7.4횞10.0 cm (3횞4 inches). Except for particularly complicated drawings that show large amounts of data, all figures are published at one page or one column width. All kinds of figures may be reduced, enlarged, or trimmed for publication by the editor.
  • 2) Figure numbers, in Arabic numerals, should appear in the figure legends. Arabic numerals should be used in the order in which the figures are referred to in the main text. In cases where more than two photographs are used with the same number, alphabet characters should be used next to the Arabic numeral (e.g., Fig. 1A, Fig. 1B).
  • 3) All pictures and photographs should be described in English, and all symbols and abbreviations should be described below the figure.
  • 4) In the case of pathologic findings or microscopic findings, the staining method and magnification should be indicated.

Manuscripts Accepted for Publication

1. Final Version
After the paper has been accepted for publication, the author(s) should submit the final version of the manuscript. The names and affiliations of the authors should be double-checked, and if the originally submitted image files were of poor resolution, higher resolution image files should be submitted at this time. The EPS, JPG, PPT, or TIF formats are the preferred digital files for photographic images. Symbols (e.g., circles, triangles, squares), letters (e.g., words, abbreviations), and numbers should be large enough to be legible even after reduction to the journal셲 column widths. All symbols must be defined in the figure captions. If references, tables, or figures are moved, added, or deleted during the revision process, renumber them to reflect the changes so that all tables, references, and figures are cited in numeric order.
2. Manuscript Corrections
Before publication, the manu script editor will correct the manuscript such that it meets the standard publication format of the JMLS. The author(s) must respond within seven days when the manuscript editor contacts the author for revisions. If the response is delayed, the manuscript셲 publication may be postponed to the next issue. The author should doublecheck corrections in the content, title, affiliation, capitalization, locations of figures, and references. Corresponding authors are responsible for corrections made after publishing.
3. Gallery Proof
The author(s) will receive the final version of the manuscript as a PDF file. Upon receipt, within two days, the Editorial Office (or printing office) must be notified of any errors found in the file. Any errors found after this time are the responsibility of the author(s) and will have to be corrected as an erratum.
4. Feedback After Publication
If the authors or readers find any errors or contents that should be revised, the revision of these can be requested from the Editorial Board. The Editorial Board may consider erratum, corrigendum, or a retraction. If there are any revisions to the article, there will be a CrossMark description to announce the final draft. If there is a reader셲 opinion on the published article in the form of a Letter to the editor, it will be forwarded to the authors. The authors may reply to the reader셲 letter. Letters to the editor and the author셲 reply may also be published.
5. How the Journal Handles Complaints and Appeals
The policy of the JMLS is primarily aimed at protecting the authors, reviewers, editors, and the publisher of the journal. If not described below, the process of handling complaints and appeals follows the guidelines of the Committee of Publication Ethics available from:
Who complains or makes an appeal?
Submitters, authors, reviewers, and readers may register complaints and appeals in a variety of cases as follows: falsification, fabrication, plagiarism, duplicate publication, authorship dispute, conflict of interest, ethical treatment of animals, informed consent, bias or unfair/inappropriate competitive acts, copyright, stolen data, defamation, or legal issues. If any individuals or institutions want to inform particular cases, they can send a letter via the contact page on our website: For complaints or appeals, concrete data with answers to all factual questions (who, when, where, what, how, why) should be provided.
Who is responsible for resolving and handling complaints and appeals?
The Editor, Editorial Board, or Editorial Office is responsible for them. A legal consultant or ethics editor may assist with the decision-making.
What may be the consequence of resolution?
It depends on the type or degree of misconduct. The consequence of the adopted resolution will follow the guidelines of the Committee of Publication Ethics (COPE).
6. Page Charges
There are no page charges to authors. A ll color figures and tables will be reproduced in full color in the online edition of JMLS at no cost to the authors, but the complete cost in the printed version of the journal will be charged to the authors. Please contact the Editorial Office if you have any questions about potential fees.
7. Confirmation of Acceptance
Once the manuscript is at the publisher, confirmation of acceptance by the JMLS may be issued.
8. E-publication Ahead-of-Print
All accepted manuscripts are subject to copyediting. Before publication, page proofs are sent to the corresponding author, who is responsible for verifying the final manuscript contents, including all copyediting changes. Once a manuscript has been typeset, copyedited, and approved by the editor and the authors, it will soon appear online in our 쏛head-of-Print section.

Further Information

Any correspondence, queries, or additional requests for information on the manuscript submission process should be sent to the JMLS Editorial Office as follows:

Editor-in-Chief: Jay Chol Choi, MD., PhD
Telephone: +82-64-754-8023

Other matters not specified in these regulations follow the decision of the Editorial Board.

The revised regulations will come into effect on April 17, 2018.

The revised regulations will come into effect on September 13, 2018.

The revised regulations will come into effect on March 5, 2019.

The revised regulations will come into effect on September 1, 2022.

The revised regulations will come into effect on January 1, 2023.

The revised regulations will come into effect on July 1, 2023.

The revised regulations will come into effect on January 1, 2024.

The revised regulations will come into effect on May 1, 2024.

Journal of
Medicine and
Life Science

Online ISSN: 2671-4922

Editorial Office
102, Jejudaehak-ro, Jeju-si, Jeju-do 63243, Republic of Korea
Tel: +82-64-754-8023    E-mail:                

Copyright © 2024 by Jeju National University Institute for Medical Science.

Developed in M2PI

Close layer
prev next